HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much ...

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on ...

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

HIMS insiders have traded $HIMS stock on the open market 143 times in the past 6 months. Of those trades, 2 have been purchases and 141 have been sales. Here’s a ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

On February 15, 2025, InvestingPro’s proprietary Fair Value model identified HIMS as significantly overvalued, with the stock trading at $60.47. Just two months later, the stock has corrected to ...

Hims & Hers Health, Inc. is anticipated to report earnings per share (EPS) of $0.11 for the current quarter, reflecting a substantial 120% increase from the same period last year. Revenue is projected ...

HIMS & HERS HEALTH INC (HIMS) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...